Mid Pharma Archives | Report Store | Pharma intelligence

show blocks helper

Sort by Price
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products ascending

Display 15 Products per page

Incyte Company Analysis

$3,000.00

PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
January 4, 2018
Select options
Biogen

$3,000.00

PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2017–27
March 7, 2017
Select options
BioMarin Company Analysis

$3,000.00

PharmaVitae explores BioMarin’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
January 4, 2018
Select options
Celgene

$3,000.00

PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 8, 2018
Select options
Acorda Company Analysis

$3,000.00

PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.
February 9, 2018
Select options
Allergan

$3,000.00

PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 10, 2018
Select options
GlaxoSmithKline

$3,000.00

PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
September 4, 2018
Select options
Gilead Company Analysis

$3,000.00

Analysis of Gilead’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
November 21, 2017
Select options
Biogen

$3,000.00

PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
September 4, 2018
Select options
Merck KGaA Company Analysis

$3,000.00

PharmaVitae explores Merck KGaA’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
December 6, 2017
Select options
Lundbeck

$3,000.00

PharmaVitae explores Lundbeck’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
August 24, 2018
Select options
Mid Pharma Outlook

$3,000.00

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.
September 28, 2016
Select options
UCB Company Analysis

$3,000.00

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
October 30, 2017
Select options
AbbVie

$3,000.00

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2017–27.
February 28, 2018
Select options
Actelion

$3,000.00

Analysis of Actelion’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
November 1, 2016
Select options

Mid Pharma

Mid Pharma

Incyte Company Analysis

Biogen

BioMarin Company Analysis

Celgene

Acorda Company Analysis

Allergan

GlaxoSmithKline

Gilead Company Analysis

Biogen

Merck KGaA Company Analysis

Lundbeck

Mid Pharma Outlook

UCB Company Analysis

AbbVie

Actelion